BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Job Trends

  Merck Plots 950-Job R&D Hub in London

  The move is in part related to Brexit, the UK’s exit from the European Union.

  November 27, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Regeneron Abandons Ship as Combo Drug Flunks Phase II Studies

  Regeneron indicated that because of disappointing results for two Phase II trials, it was ending its development of angiopoietin2 antibody nesvacumab as an addition to Eylea.

  November 27, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Deals

  Why Shire Should Spin Off Its Neuroscience Biz and Merge With This Maryland Pharma

  Kenneth Pittman, writing for Seeking Alpha, takes a look at why Shire is thinking of unloading its neuroscience division and suggesting an alternative.

  November 27, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Teva Expected to Fire Up to 1,700 Workers in Israel, U.S.

  News of the layoffs comes hard on the heels of the company’s credit rating having been cut to junk status by Fitch Rating.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Job Trends

  Qiagen Plans to Create Up to 800 Jobs at New UK Campus Post Brexit

  Qiagen’s investment will be an expansion of its current operations in that northern England city.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• BioMidwest

  3 Top Diabetes Biotechs to Buy Into Right Now

  Diabetes is huge problem for Americans.

  November 27, 2017

   · 

  1 min read
• 

  Biotech Bay

  Bay Area’s Medeor Therapeutics Bags $57M

  The financing will be used to push its Phase III clinical program of MDR-101 in living donor HLA-matched kidney transplant patients.

  November 27, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Little-Known Synthorx Names Former Cleave CEO as New Leader

  Shawver, a long-time industry veteran, will assume the role of president, CEO and director of Synthorx.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Teva Shakes Up C-Suite in Restructuring

  Since taking over at Teva earlier this fall, Kare Schultz has been swiftly moving to shore up the finances and pay down the massive debts of the beleaguered pharmaceutical company.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• Immunochina Lands $7.5M for CAR-T Drug Trials

  Immunochina raised $7.5M to support clinical trials of its CAR-T product for lymphoma.

  November 27, 2017

   · 

  1 min read